Jean-Jacques Kiladjian: Interferon-Alpha in Polycythemia Vera Balancing Efficacy and Autoimmune Risk
Jean-Jacques Kiladjian, Head of Clinical Research Department of Inserm, Professor of Medicine at the University of Paris Cité, President of the FIM, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in HemaSphere, adding:
“Interferon-alpha is a major treatment for Polycythemia Vera, but its use requires some precautions, particularly due to its immunomodulatory properties. In this article, we review the immune-related complications associated with interferon-alpha therapy and discuss strategies for their prevention and management.
A pre-treatment evaluation is necessary, and discussion with a specialist is often helpful to determine whether interferon can be safely used and how patients should be monitored in the presence of pre-existing autoimmune disease or signs of autoimmunity.”
Title: Autoimmunity and peginterferon therapy for polycythemia vera
Authors: Etienne Rivière, Alexandre Guy, Olivier Mansier, Clémence Mediavilla, Jean-Jacques Kiladjian, Chloé James, Patrick Blanco, Estibaliz Lazaro, Jean-François Viallard
More posts featuring Jean Jacques Kiladjian on Hemostasis Today.
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD
-
Sep 29, 2026, 10:49Alison Davey: The Vital Role of Community Support in Bleeding Disorders
-
Sep 29, 2026, 10:36Abdul Muqtadir Abbasi: 5 Questions to Ask When the CBC Is Abnormal
-
Sep 29, 2026, 10:28Manu Morales Sánchez: DOACs in Intermediate Risk Atrial Fibrillation
-
Sep 29, 2026, 09:59William Sauer: Ablation in Patients With LAAO Devices
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia